Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research In Brief

This article was originally published in The Tan Sheet

Executive Summary

Ibuprofen & Alzheimer's: Analgesic may protect against disease due to inhibition of amyloid-beta 42 peptide, a protein found in plaque that kills brain cells of Alzheimer's patients, researchers report in Nov. 8 Nature. Sascha Weggen, UC-San Diego, et al., found 250 mM ibuprofen dissolved in ethanol decreased Aß42 peptide in cultured cells by up to 80%. Also, ibuprofen treatment in three-month old mice "resulted in a highly significant 39% decrease in levels of Aß42...compared with mock-treated animals," researchers report. However, aspirin, naproxen, other NSAIDs showed negative results, indicating a lack of ability to lower Aß42 levels. Although researchers previously believed NSAIDs' mechanism of action was their anti-inflammatory properties, Weggen et al. note "this Aß42 activity may be an important criterion to consider in...trials of NSAIDs for the treatment of Alzheimer's disease"...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093267

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel